Larimar Therapeutics Stock Today
| LRMR Stock | USD 2.95 0.08 2.64% |
PerformanceVery Weak
| Odds Of DistressLow
|
Larimar Therapeutics is selling at 2.95 as of the 26th of February 2025; that is 2.64 percent decrease since the beginning of the trading day. The stock's lowest day price was 2.88. Larimar Therapeutics has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 28th of November 2024 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of June 2014 | Category Healthcare | Classification Health Care |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreichs ataxia, a rare, progressive, and fatal genetic disease. The company has 63.81 M outstanding shares of which 5.07 M shares are now shorted by private and institutional investors with about 9.28 trading days to cover. More on Larimar Therapeutics
Moving against Larimar Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Larimar Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Carole MD | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsLarimar Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Larimar Therapeutics' financial leverage. It provides some insight into what part of Larimar Therapeutics' total assets is financed by creditors.
| |||||
Larimar Therapeutics (LRMR) is traded on NASDAQ Exchange in USA. It is located in Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004 and employs 42 people. Larimar Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 188.23 M. Larimar Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 63.81 M outstanding shares of which 5.07 M shares are now shorted by private and institutional investors with about 9.28 trading days to cover.
Larimar Therapeutics currently holds about 54.92 M in cash with (33.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.1, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Larimar Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Larimar Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Larimar Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Larimar Therapeutics. Please pay attention to any change in the institutional holdings of Larimar Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Larimar Ownership Details
Larimar Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 886.4 K | |
| State Street Corp | 2024-12-31 | 842.9 K | |
| Mangrove Partners | 2024-12-31 | 770.2 K | |
| Fred Alger Management, Llc | 2024-12-31 | 737.6 K | |
| Woodline Partners Lp | 2024-12-31 | 622.7 K | |
| Renaissance Technologies Corp | 2024-12-31 | 513.5 K | |
| Altium Capital Management, Lp | 2024-12-31 | 505 K | |
| Sphera Funds Management Ltd. | 2024-12-31 | 455.6 K | |
| Northern Trust Corp | 2024-12-31 | 376.5 K | |
| Deerfield Management Co | 2024-12-31 | 21.2 M | |
| Hhg Plc | 2024-12-31 | 6.4 M |
Larimar Therapeutics Historical Income Statement
Larimar Stock Against Markets
Larimar Therapeutics Corporate Management
| Gopi MBA | Chief Officer | Profile | |
| DO Sr | Chief Officer | Profile | |
| Francis Conway | VP Controller | Profile | |
| Sr DO | Chief Officer | Profile | |
| John Berman | Vice Administration | Profile |
Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.